Dr. Ali Al-Ghamrawi, Head of the Egyptian Drug Authority (EDA), denied any increase or adjustment in medicine prices at the present time, citing several reasons, most notably the stability of the US dollar exchange rate and the availability of raw materials.

In a press statement during a press conference, Al-Ghamrawi explained that the Pricing Committee sets several criteria when adjusting or determining drug prices, primarily the exchange rate. He pointed out that if the dollar exchange rate decreases, drug prices will also be reduced, which is a natural outcome according to the pricing framework.

Drug Tracking System
Al-Ghamrawi confirmed that the EDA has begun the first steps of implementing the Drug Tracking System, with the first phase to be activated next November. This is part of a long-term plan aimed at regulating the pharmaceutical market, combating smuggling and counterfeiting, and achieving transparency in the pharmaceutical supply chain.

He clarified that this system represents a “long journey” that will span between 3 to 5 years until it is fully applied to all drug packages in the Egyptian market. He noted that the decision published in the official gazette marks the official first step for the system’s launch.

The EDA Head stressed that the tracking system will allow every drug package to be monitored from production until it reaches the patient’s hands. This will enhance the state’s ability to address violations and ensure the organized and safe availability of medicines.

Copied from Alahram